Clinical trials: Sclerosis, Multiple
- Condition Sclerosis, Multiple
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Study Using 3 Different Formulations of Firategrast
This study will investigate how 3 types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01416363
- Testing
- Firategrast immediate release tablet, Firategrast modified release tablet, Firategrast gastro-retentive solution
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Pregnancy
Kesimpta (Ofatumumab) Pregnancy Registry
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
- Trial name
- NCT05634967
- Testing
- Kesimpta
- Where
- United States
- Volunteers
- 725 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers
In this clinical study, the safety and tolerability of GNbAC1 as a treatment for MS patients will be evaluated in healthy male volunteers.
- Trial name
- NCT02452996
- Testing
- GNbAC1
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis
First-in-Human Study With GNbAC1 in Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of single ascending doses of GNbAC1 in healthy male subjects.
- Trial name
- NCT01699555
- Testing
- GNbAC1
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GeNeuro Innovation SAS
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Multiple Sclerosis
EPID Multiple Sclerosis Pregnancy Study
Multiple Sclerosis (MS) is the most common chronic neurologic disability in young adult females in their childbearing ages. Little evidence is available regarding the association between exposure to IFN-beta (β) products and…
- Trial name
- NCT02749396
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd
- Where
- Finland
- Volunteers
- 2,089 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
- Trial name
- NCT04933552
- Testing
- Siponimod
- Where
- United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis Healthy Subjects
Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants
Primary Objective: To assess the pharmacokinetic parameters of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants.
- Trial name
- NCT04982991
- Testing
- RIPK1 inhibitor
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.
- Trial name
- NCT02201849
- Testing
- Study Drug, Active Control
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Biogen
Alzheimer Disease, Mild Cognitive Impairment
Longitudinal Cognitive Assessment by BoCA
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia
- Trial name
- BoCA (NCT04114994)
- Testing
- Boston Cognitive Assessment (BoCA)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Multiple Sclerosis
A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
Primary Objective: To assess the pharmacokinetic (PK) parameters of teriflunomide after a single oral dose of 14 mg administration in Chinese healthy subjects Secondary Objective: To assess the safety and tolerability after a…
- Trial name
- NCT02046629
- Testing
- Teriflunomide HMR1726, cholestyramine
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.
Multiple sclerosis (MS) is a chronic progressive neurological autoimmune disease, that gradually affects patient's quality of life. There are about 2.5 millions patients world wide, with an increasing cost Burdon.
- Trial name
- NCT03486665
- Testing
- Blood Sampling, CSF Sampling
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bioimmunate
Multiple Sclerosis
An Observational Study on Teriflunomide-exposed Pregnancies
Primary Objective: To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies.
- Trial name
- NCT03198351
- Testing
- Teriflunomide (HMR1726)
- Where
- 2 sites in United States, Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
Evaluation of the Microbiome in Multiple Sclerosis
To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.
- Trial name
- NCT05844826
- Testing
- SIMBA Capsule
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Multiple Sclerosis
PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers
This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.
- Trial name
- NCT04941781
- Testing
- PIPE-307
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Multiple Sclerosis
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
This was a Phase 2, randomized, double-blind, placebo-controlled 2 parallel-arm study to assess the effect on serum neurofilament light chain (sNfL), safety and tolerability of oral SAR443820 compared to placebo in male and…
- Trial name
- NCT05630547
- Testing
- SAR443820
- Where
- 35 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers
Biogen Idec has developed a novel process to manufacture Interferon beta-1a (INFB), the active ingredient of Avonex®, that does not include fetal bovine serum (FBS).
- Trial name
- NCT01500408
- Testing
- Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Comparative Oral Bioavailability Study of MT-1303
The purpose of this study is to assess the comparative oral bioavailability of a Formulation B versus the Formulation A of MT-1303.
- Trial name
- NCT02310048
- Testing
- MT-1303-FormA, MT-1303-FormB
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Multiple Sclerosis (MS)
Avonex®: Safety, Blood Levels and Effects
The primary objective was to determine the tolerability of a new inhaled formulation of interferon beta-1a when given as a single dose, when given once per week for 4 weeks, and compared with standard intramuscular (IM) AVONEX®…
- Trial name
- C-851 (NCT01863069)
- Testing
- Interferon beta 1a, (IM) AVONEX®
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.